12/4
06:27 pm
gmab
Assessing Genmab (CPSE:GMAB) Valuation After Its Recent Share Price Strength [Yahoo! Finance]
Low
Report
Assessing Genmab (CPSE:GMAB) Valuation After Its Recent Share Price Strength [Yahoo! Finance]
11/27
07:11 pm
gmab
Genmab (GMAB) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Genmab (GMAB) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
11/25
09:13 am
gmab
Bicara Therapeutics: Intriguing Opportunity Given Rival Merus' $8B Buyout [Seeking Alpha]
Low
Report
Bicara Therapeutics: Intriguing Opportunity Given Rival Merus' $8B Buyout [Seeking Alpha]
11/20
03:51 pm
gmab
Grant of Restricted Stock Units and Warrants to Employees in Genmab [Yahoo! Finance]
Low
Report
Grant of Restricted Stock Units and Warrants to Employees in Genmab [Yahoo! Finance]
11/19
07:04 pm
gmab
Genmab (CPSE:GMAB) Valuation in Focus After Recent Share Price Pullback [Yahoo! Finance]
Medium
Report
Genmab (CPSE:GMAB) Valuation in Focus After Recent Share Price Pullback [Yahoo! Finance]
11/19
12:55 pm
gmab
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Low
Report
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
11/18
11:34 am
gmab
AbbVie, Genmab win FDA label expansion for Epkinly in follicular lymphoma [Seeking Alpha]
Low
Report
AbbVie, Genmab win FDA label expansion for Epkinly in follicular lymphoma [Seeking Alpha]
11/18
11:30 am
gmab
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
Low
Report
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
11/18
11:30 am
gmab
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
Low
Report
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
11/10
11:01 am
gmab
Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes [Yahoo! Finance]
Low
Report
Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes [Yahoo! Finance]
11/10
08:03 am
gmab
Genmab A/S (NASDAQ:GMAB) had its price target raised by analysts at HC Wainwright from $40.00 to $41.00. They now have a "buy" rating on the stock.
Low
Report
Genmab A/S (NASDAQ:GMAB) had its price target raised by analysts at HC Wainwright from $40.00 to $41.00. They now have a "buy" rating on the stock.
11/10
07:42 am
gmab
Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility [Yahoo! Finance]
Low
Report
Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility [Yahoo! Finance]
11/8
01:17 pm
gmab
11/8
06:49 am
gmab
Genmab A/S (GMAB) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Genmab A/S (GMAB) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/6
07:02 pm
gmab
Genmab A/S (NASDAQ:GMAB) was given a new $48.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Genmab A/S (NASDAQ:GMAB) was given a new $48.00 price target on by analysts at Truist Financial Corporation.
11/6
11:02 am
gmab
Genmab Announces Financial Results for the Nine Months of 2025
Low
Report
Genmab Announces Financial Results for the Nine Months of 2025
11/4
05:49 am
gmab
Genmab A/S (NASDAQ:GMAB) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Genmab A/S (NASDAQ:GMAB) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
11/3
09:05 am
gmab
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
Low
Report
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
10/27
10:07 am
gmab
Genmab A/S (NASDAQ:GMAB) had its "buy" rating reaffirmed by analysts at Johnson Rice.
Low
Report
Genmab A/S (NASDAQ:GMAB) had its "buy" rating reaffirmed by analysts at Johnson Rice.
10/27
10:07 am
gmab
Genmab A/S (NASDAQ:GMAB) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Genmab A/S (NASDAQ:GMAB) had its "buy" rating reaffirmed by analysts at HC Wainwright.
10/18
06:05 am
gmab
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer [Yahoo! Finance]
Medium
Report
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer [Yahoo! Finance]
10/18
06:00 am
gmab
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
Medium
Report
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
10/15
08:12 am
gmab
Genmab A/S (NASDAQ:GMAB) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Low
Report
Genmab A/S (NASDAQ:GMAB) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
10/14
06:23 am
gmab
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025
Low
Report
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025
10/13
02:43 am
gmab
Genmab (CPSE:GMAB) Valuation Insights Following Recent Share Price Climb [Yahoo! Finance]
Medium
Report
Genmab (CPSE:GMAB) Valuation Insights Following Recent Share Price Climb [Yahoo! Finance]